https://doi.org/10.55788/b101c951
Environmental factors, modulated by genetics, contribute to the pathogenesis of MS, which may result in a unique metabolic signature. On the other hand, the acute inflammatory processes that lead to brain tissue damage, may also contribute to this metabolomic signature. Dr Vinicius Schoeps and colleagues (University of California, CA, USA) performed an in-depth analysis of the circulating lipidome profile and its association with disease activity [1]. To this end, they analysed blood samples from a prospective cohort of 435 paediatric-onset MS patients. At sample collection, 285 (66%) patients were women, median age was 16.2 years, 68% were treatment-naïve, median Expanded Disability Status Scale (EDSS) score was 1.5, and median follow-up was 4.12 years (clinical) and 3.89 years (MRI). Dr Schoeps said they used adolescents as study participants because at that age confounding factors that could influence lipid levels are less likely to occur.
A total of 2,104 metabolites were measured; of the 489 that were chemically characterised, 16 were associated with subsequent disease activity. Weighted Correlation Network Analysis (WGCNA) showed that, when clustering all PUFAs to predict outcomes in MS, there was a consistent estimated reduction in multiple outcomes, such as relapse rate (RR 0.89; 95% CI 0.79–1.00; P=0.056). The prespecified threshold in false discovery rate was not reached, however (false discovery rate >0.999).
Dr Schoeps noted that ω-3 PUFAs were consistently associated with protective effects on clinical and MRI outcomes. Examples of ω-3 PUFAs are fish oil, walnuts, and chia seeds. On the other hand, ω-6 PUFAs such as sunflower, corn, and soy-bean oils, were associated with MS worsening.
Focusing on oxylipids, ω-3 PUFA derivatives (8-HETE, 12-HEPE, 9-HETE, 5-HETE, 16,17-DiHDoPE) exerted anti-inflammatory activity, while ω-6 PUFA derivatives, most notably 10-HODE and 12-HODE, exerted mostly pro-inflammatory activity. A notable exception was arachidonic acid, which showed consistent anti-inflammatory effects.
“Structural lipids are a by-product of inflammation,” Dr Schoeps concluded, “while PUFAs modulate immune responses and may be responsible for changing the future risk of disease activity.”
- Schoeps V, et al. Serum lipidomics and disease activity in pediatric-onset multiple sclerosis: a nation-wide prospective cohort study. O079, MSMilan 2023, 11–13 October, Milan, Italy.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Smouldering inflammation detectable even in the earliest stages of MS Next Article
An update on evolving treatment algorithms for NMOSD and MOGAD »
« Smouldering inflammation detectable even in the earliest stages of MS Next Article
An update on evolving treatment algorithms for NMOSD and MOGAD »
Table of Contents: MSMilan 2023
Featured articles
Letter from the Editor
Real-world data supports ocrelizumab prior to conception
Progressive MS
Early initiation of highly active treatment associated with a lower risk of SPMS
Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients
Paediatric MS
Prioritising high efficacy therapies in children with MS
Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity
NMOSD & MOGAD
An update on evolving treatment algorithms for NMOSD and MOGAD
Women’s Health
Rate of grey matter brain atrophy accelerates after menopause
Real-world data supports ocrelizumab prior to conception
Miscellaneous
New insights into the contribution of EBV to MS pathogenesis
COVID-19 infection associated with higher MS relapse rate
Telerehabilitation effective in improving MS symptoms in patients with moderate disability
Curing MS
Understanding what an MS cure means and what it takes
Prodromal MS
Progressive brain tissue loss precedes the onset of clinical MS by years
Sickness absence rate increases years before clinical onset of MS
Treatment Trials and MS Strategies
Early intensive treatment enhances long-term clinical outcomes
Oral glycolipid shows promise in the treatment of MS, especially SPMS
Fenebrutinib shows rapid reduction of new Gd+ T1 lesions
Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients
Biomarkers & Imaging
χ-separation can assess the effects of tissue destruction in early MS lesions
High sGFAP levels are associated with disease progression, independent of NfL or relapse activity
Broad rim lesions correlate with a rapidly progressive MS phenotype
Smouldering inflammation detectable even in the earliest stages of MS
Related Articles
August 18, 2021
No higher early MS relapse frequency after stopping ponesimod
November 8, 2019
Sustained reduction in disability progression with ocrelizumab
September 10, 2020
Alemtuzumab efficacy and safety data of over 9 years
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy